Korro to Present at the 2026 Jefferies Global Healthcare Conference
Rhea-AI Summary
Korro (Nasdaq: KRRO) announced that CEO and President Ram Aiyar, Ph.D., will present at the 2026 Jefferies Global Healthcare Conference in New York.
The presentation is scheduled for Thursday, June 4, 2026, at 4:20 pm ET, highlighting Korro’s OPERA RNA-editing platform and genetic medicine focus.
Positive
- None.
Negative
- None.
News Market Reaction – KRRO
In the May 27 session, KRRO gained 11.60%, reflecting a significant positive market reaction. Argus tracked a peak move of +8.0% during that session. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 19 | Pipeline candidate update | Positive | -2.7% | Selected KRRO-111 AATD candidate with strong preclinical RNA-editing metrics. |
| May 15 | Inducement option grant | Neutral | -2.1% | Granted 3,000-share stock option under inducement plan at $11.20 exercise price. |
| May 07 | Earnings and update | Positive | -3.4% | Reported Q1 2026 cash of $157.1M after $85M placement and long cash runway. |
| May 05 | Investor conferences | Positive | +6.0% | Announced May 2026 investor conference participation and executive fireside chats. |
| Apr 16 | Scientific presentations | Positive | -1.5% | Outlined multiple OPERA platform data presentations at scientific conferences. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
KRRO has often traded weakly after fundamentally positive updates, with several pipeline and financial milestones followed by negative 24h moves.
Over recent months, KRRO highlighted multiple RNA-editing milestones and financing steps. On May 7, 2026, Q1 results showed $157.1M in cash and runway into H2 2028, yet shares fell 3.37%. Selection of AATD candidate KRRO-111 on May 19, 2026 also saw a 2.71% drop. By contrast, a May 5, 2026 investor-conference announcement coincided with a 5.96% gain. Today’s Jefferies appearance fits an ongoing strategy of active conference visibility alongside pipeline advancement and recent capital raises.
Key Terms
oligonucleotide promoted editing of rna (opera®) medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 2026 Jefferies Global Healthcare Conference being held in New York, NY on June 2nd- 4th, 2026. Dr. Aiyar’s presentation will take place on Thursday, June 4, 2026, at 4:20 pm ET.
About Korro
Korro is a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases. OPERA provides precise, tissue-directed delivery of oligonucleotides that modify the targeted native mRNA transcript to repair or form a de-novo protein with enhanced functionality. The platform combines a suite of capabilities consisting of sophisticated knowledge of transcription biology through ADAR proteins (Adenosine Deaminases Acting on RNA), machine learning optimization of oligonucleotides, linker chemistry expertise, along with use of a highly targeted tissue-specific delivery methodology. As such, the OPERA platform has enabled Korro to generate and advance a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, providing precise yet transient single base edits to produce therapeutic proteins with augmented activity versus its endogenous counterpart. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary OPERA platform with precedented delivery modalities, including N-acetylgalactosamine (GalNAc) conjugated for delivery for subcutaneous administration, manufacturing know-how, and established regulatory pathways of approved oligonucleotide medicines. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.
Korro intends to use its Investor Relations website, LinkedIn, and X (Twitter) as means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Korro’s Investor Relations website and follow @KorroBio on LinkedIn, and X (Twitter), in addition to following Korro’s press releases, SEC filings, public conference calls, presentations, and webcasts.
Korro Bio Contact Information
Investor & Media Contact
Malini Chatterjee, Ph.D
Blueprint Life Science Group
mchatterjee@bplifescience.com or ir@korrobio.com
917.330.4269
